SCHEMBL6355462

SCHEMBL6355462

Cc1cc(C)cc(NC(=O)Cc2ccc(OC3(C(=O)N[C@@H](CC(C)C)C(=O)O)CCCC3)cc2)c1

nearest known ligand 0.43

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 3/20 0.43
CTSL P07711 1/20 0.41
NTSR1 P30989 1/20 0.41
MMP1 P03956 1/20 0.39
MAPK1 P28482 1/20 0.38
ATM Q13315 1/20 0.38
MEN1 O00255 1/20 0.37
KMT2A Q03164 1/20 0.37
POLB P06746 1/20 0.37
ITGB1 P05556 1/20 0.37
ITGA4 P13612 1/20 0.37
MAPT P10636 1/20 0.37
CTSK P43235 2/20 0.36
L3MBTL1 Q9Y468 1/20 0.36
LMNA P02545 1/20 0.36
CASP1 P29466 1/20 0.36
CASP3 P42574 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6353468 1.00 ALDH1A1 (0.43) ALDH1A1CTSLNTSR1MMP1MAPK1
SCHEMBL6362113 0.91 ALDH1A1 (0.38) ALDH1A1MEN1KMT2APOLBITGB1
SCHEMBL6357946 0.91 ALDH1A1 (0.38) ALDH1A1MEN1KMT2APOLBITGB1
SCHEMBL6361418 0.90 TMPRSS15 (0.42) ALDH1A1MEN1KMT2APOLBCTSK
SCHEMBL6362871 0.89 ALDH1A1 (0.39) ALDH1A1MEN1KMT2APOLBMAPT
SCHEMBL6359207 0.89 ALDH1A1 (0.39) ALDH1A1MEN1KMT2APOLBMAPT
SCHEMBL6362766 0.88 ITGB3 (0.48) MEN1KMT2AITGB1ITGA4L3MBTL1
SCHEMBL6361384 0.88 ITGB3 (0.48) MEN1KMT2AITGB1ITGA4L3MBTL1
SCHEMBL6362802 0.88 TMPRSS15 (0.39) ALDH1A1MMP1MEN1KMT2APOLB
SCHEMBL6361820 0.87 ITGB3 (0.41) MMP1ITGB1ITGA4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20050154062-A1 Substituted chiral allosteric hemoglobin modifiers ALLOS THERAPEUTICS, INC. 2005-07-14 US disclosed
US-6894185-B2 Substituted chiral allosteric hemoglobin modifiers Allós Therapeutics, Inc. (US) 2005-05-17 US disclosed
US-20030130523-A1 Substituted chiral allosteric hemoglobin modifiers ABRAHAM DONALD J (US) 2003-07-10 US disclosed
US-6486342-B1 Substituted chiral allosteric hemoglobin modifiers VIRGINIA COMMONWEALTH UNIVERSITY 2002-11-26 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030130523-A1 Substituted chiral allosteric hemoglobin modifiers HBZ, HBB, HBG2 ALDH1A1 4454/4885CTSL 4098/4885NTSR1 3875/4885
US-20050154062-A1 Substituted chiral allosteric hemoglobin modifiers HBZ, HBB, HBG2 ALDH1A1 4454/4885CTSL 4098/4885NTSR1 3875/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.